No Data
INNOVENT BIO (01801): The third-generation EGFR TKI targeted drug for lung cancer, Aotinib (Leratinib tablets), has been approved by the NMPA for first-line indications.
INNOVENT BIO (01801) announced the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (T...
Express News | Innovent Biologics - Third-Generation Egfr Tki Limertinib Received Approval From Nmpa
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Hong Kong stock midday review | Hang Seng Index down 1.21% Hang Seng Biotechnology Index strengthens against the trend.
The Hang Seng Biotechnology Index rose against the market trend, with Institutions being Bullish on the overseas expansion of Innovative Drugs and the domestic substitution of certain biopharmaceutical companies.
Hong Kong stock concept tracking | AKESO's new drug clinical trial has achieved success again, with Innovative Drugs in China taking on a significant role in the Global diagnosis and treatment of lung cancer (with related stocks attached).
AKESO's bispecific antibody drug, Ivosidenib (PD-1/VEGF bispecific antibody), has once again outperformed PD-1 in a head-to-head trial, this time challenging the combination therapy of BEIGENE's Tislelizumab.
Awarded seven ASCO oral presentations: INNOVENT BIO's IBI363 (PD-1/IL-2α-bias) leads multiple pipeline products at the USA Clinical Oncology Society 2025 conference.
San Francisco, USA and Suzhou, China, April 24, 2025 /PR Newswire/ -- INNOVENT BIO Pharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to the research, production, and sales of Innovative Drugs in significant disease areas such as oncology, autoimmunity, metabolism, cardiovascular diseases, and ophthalmology, today announced that it will present a series of clinical data on its oncology innovation pipeline at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), including IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC) multiple...
